Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RBC BioscienceROCO:6848 +4.86%76 PB Ratio is 1.09 as of Jul. 17, 2026, which is 11% above its 10-year median of 0.98. GuruFocus rates ROCO:6848 with a GF Score™ of 76/100 and a GF Value™ of NT$19.91 (Fairly Valued). The stock has 7 warning signs investors should review. Among 1,227 Biotechnology companies, RBC Bioscience ranks better than 80.44% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-17), RBC Bioscience's share price is NT$20.50. RBC Bioscience's Book Value per Share for the quarter that ended in Dec. 2025 was NT$18.81. Hence, RBC Bioscience's PB Ratio of today is 1.09.
The historical rank and industry rank for RBC Bioscience's PB Ratio or its related term are showing as below:
ROCO:6848'
s PB Ratio Range Over the Past 10 Years
Min: 0.73 Med: 0.98 Max: 3.16
Current: 1.09
During the past 9 years, RBC Bioscience's highest PB Ratio was 3.16. The lowest was 0.73. And the median was 0.98.
ROCO:6848's PB Ratio is ranked better than 80.44% of 1227
companies
in the Biotechnology industry
Industry Median: 2.82
vs ROCO:6848: 1.09
During the past 12 months, RBC Bioscience's average Book Value Per Share Growth Rate was 7.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 2.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 6.00% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of RBC Bioscience was 44.30% per year. The lowest was -1.00% per year. And the median was 20.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
RBC Bioscience PB Ratio Related Terms
RBC Bioscience PB Ratio Historical Data
* Premium members only.
The historical data trend for RBC Bioscience's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6848 vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, RBC Bioscience's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RBC Bioscience PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RBC Bioscience's PB Ratio distribution charts can be found below:
* The bar in red indicates where RBC Bioscience's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
RBC Bioscience's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
RBC Bioscience (ROCO:6848) has a PB Ratio of 1.09 as of Jul. 17, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on RBC Bioscience and its competitors. This is 11% above median its historical median of 0.98. Over the past decade, RBC Bioscience's PB Ratio has ranged from 0.73 to 3.16. According to the industry distribution chart, RBC Bioscience ranks #240 out of 1227 companies in the Biotechnology industry, placing it in the top 19.6%.
Is RBC Bioscience's PB Ratio too high?
RBC Bioscience's current PB Ratio of 1.09 is 11% above median its 10-year median of 0.98. Over the past 10 years, this metric has ranged from a low of 0.73 to a high of 3.16. The Biotechnology industry median PB Ratio is 2.82. RBC Bioscience's value of 1.09 is 61.3% below this industry median. Based on the distribution chart, RBC Bioscience ranks #240 out of 1227 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, RBC Bioscience has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RBC Bioscience's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RBC Bioscience ranks #240 out of 1227 companies for PB Ratio. This places RBC Bioscience in the top 20% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.82. RBC Bioscience's value of 1.09 is 61.3% below this benchmark. Historically, RBC Bioscience's own PB Ratio has ranged from 0.73 to 3.16 over the past decade. While the company's 10-year median is 0.98 vs. the industry median of 2.82, RBC Bioscience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RBC Bioscience's current PB Ratio of 1.09 is 61.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on RBC Bioscience and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RBC Bioscience's current PB Ratio is 1.09, which is 11% above median its own 10-year median of 0.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RBC Bioscience stock overvalued right now?
Based on GuruFocus' analysis, RBC Bioscience (ROCO:6848) is currently considered Fairly Valued. The stock's GF Value™ is NT$19.91, compared to a current price of NT$20.50 — trading 3% above its estimated fair value. The current PB Ratio is 1.09, which is 11% above median its 10-year median of 0.98 and 61.3% below the Biotechnology industry median of 2.82. RBC Bioscience's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For RBC Bioscience (ROCO:6848), the current PB Ratio is 1.09 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RBC Bioscience (ROCO:6848) Overvalued in 2026?
Based on GuruFocus' analysis, RBC Bioscience stock appears to be overvalued.
The current stock price of NT$20.50 is trading 3% above its estimated GF Value™ of NT$19.91.
GuruFocus considers RBC Bioscience to be Fairly Valued.
Key valuation signals for ROCO:6848:
PB Ratio: 1.09 (11% above median its 10-year median of 0.98)
GF Value™: NT$19.91 vs. price of NT$20.50 (3% above fair value)
Industry Position: 61.3% below the Biotechnology median (#240 of 1227)
No single metric tells the full story. See the ROCO:6848 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RBC Bioscience Corp is a bio-sciences company. Its products include the manufacture and sale of molecular biological medical diagnosis and research reagents, gene extraction automatic testing instruments, and gene extraction reagent tissues.
76GF Score
Get the complete analysis for ROCO:6848
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6848 has been successfully added to your 
